Weeding Mendel’s Garden: Can We Hoe Dubious Genetic Associations?
original papers and understand enough to know whether you can trust it. Marc Cruts: I believe that it is
Upcoming Webinars
No Upcoming Webinars AvailableALL WEBINARS
117 RESULTS
You searched papers/many-are-called-yet-few-are-chosen-are-neuropsychiatric-clinical-trials-letting-us-down
Sort By:
- Most Recent
- Most Commented
- Most Relevant
“Network Epicenters” in Healthy Connectome Predict Dementia
the papers and an accompanying editorial freely available for download to Alzforum readers until 15
Clearing the Fog Around Aβ Oligomers
all papers reporting the effects of aggregated proteins clearly state the exact source of the protein,
Resolving Controversies on the Path to AD Therapeutics
in the Phase 3 trial. However, I also refer to our Nature Reviews Drug Development paper, where I lay
Slow Aβ; Clearance Is ApoE4’s Modus Operandi in Late-Onset AD
generously granted free access to Castellano et al. for Alzforum readers. For a brief summary of the paper
Intraneuronal Aβ: Was It APP All Along?
its role in AD pathogenesis. The Guest Moderator was David Holtzman. Paper Under Discussion.
Two New Sets of Diagnostic Criteria—Which Is Right for Your Clinic?
2011). The papers followed a previous release of draft guidelines at the July 2010 ICAD conference in
Grasping the Shadow Force: Immune Cells in ALS
When two biological networks as complex as the nervous and immune systems cross paths, you know the interaction is not going to be simple. Add in neurodegeneration—such as amyotrophic lateral sclerosis—and it creates a web that will take many scientists t
Reimagining Alzheimer's Disease—Time for Bright New Ideas?
Alois Alzheimer made a major breakthrough when he discovered senile plaques in the brains of dementia patients, and his work ultimately led to the discovery of amyloid-β and to the amyloid cascade hypothesis. But that cascade is only part of a much bigger
Herpes Simplex and Alzheimer’s—Time to Think Again?
On Thursday, 24 February 2011, Ruth Itzhaki, University of Manchester, U.K.; Elisa Porcellini, University of Bologna, Italy; Luc Letenneur, INSERM, Bordeaux, France, and Richard Smeyne, St. Jude Children’s Research Hospital, Memphis, Tennessee, shared som
The AD8—Dementia Screen Ready for Prime Time?
Have you been waiting for a quick yet reliable test for early dementia? The AD8 might be your answer. The interview-based screening tool detects early cognitive impairment, has been validated against the clinical dementia rating scale and against neuropsy
Untapped Resource? New Study to Boost Acceptance of CSF Analysis
LP, etc.)? A: This is published in the Nature Rev Neurol paper (see Blennow et al., 2010). Q: We are
Microdissection and Microarrays: Analyzing Selective Cell Vulnerability
As Tolstoy wrote in Anna Karenina, “Happy families are all alike; every unhappy family is unhappy in its own way.” The same might be said of the brain. Normal brains look and behave similarly, but those affected by different neurodegenerative diseases are
Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
measure as a primary outcome in this population. Notably, a recent paper demonstrates the utility of
Collective Thought at Its Best: Let’s Contemplate the Centennial
One hundred years ago, in January of 1907, Alois Alzheimer published his landmark paper about
Have a topic idea for a webinar? We would love to hear it. Send an email to webinars [at] alzforum [dot] org.
Current Filters
- Keyword: papers/many-are-called-yet-few-are-chosen-are-neuropsychiatric-clinical-trials-letting-us-down x